|Pharmacology and Nutritional Sciences||Barnstable Brown Obesity and Research Day||Equipment Calendars|
The Phase II Center of Research in Obesity and Cardiovascular Disease (COCVD) at the University of Kentucky is supported by a $11.3 million, five-year award (P20 GM103527) from the National Institute of General Medical Sciences (NIGMS). The NIGMS is a part of the National Institutes of Health (NIH) that supports thematic, multidisciplinary Centers of Biomedical Research Excellence (COBRE) across the country through its Institutional Development Award (IDeA) program.
The primary activity of the COCVD is to identify mechanisms linking the epidemic of obesity to the high incidence of cardiovascular diseases in the obese population. This research focus is used as a platform to develop promising junior investigators who serve as principal investigators on research projects that address timely and significant questions related to obesity and cardiovascular disease. COCVD has assembled a group of established extramurally funded scientists who provide mentoring for the investigators. This mentorship facilitates the development of the investigators’ research projects and enhances their success in competing for independent NIH-funded research.
As a multidisciplinary collaborative, COCVD encourages the development of research infrastructure and shared use core facilities that support and extend research methods critical to the study of obesity and cardiovascular disease. Additionally, COCVD facilitates symposia and seminars for its research participants, and awards pilot/feasibility grants to non-COCVD faculty members to initiate new research focused on obesity and cardiovascular disease.
Research Support Services and Equipment
It is imperative that all users of COBRE Core services and/or equipment, including radiotelemetry, EchoMRI, DEXA-IR, metabolism chambers, pathology services, MS or bioplex analytical services and the statistical analysis that Dr. Richard Charnigo provides, must cite the COBRE NIH grant using this language as an example:
"Research reported in this [publication, release] was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103527.”
Before utilizing research equipment on the fifth floor of the CT Wethington Building and other locations, please review this overview on the use and handling of equipment.
Myeloid-specific IκB kinase β deficiency decreases atherosclerosis in low-density lipoprotein receptor-deficient mice.
Park SH, Sui Y, Gizard F, Xu J, Rios-Pilier J, et al.
Arteriosclerosis, thrombosis, and vascular biology. 2012; 32(12):2869-76. NIHMSID: NIHMS567690
Lipid phosphate phosphatase (LPP3) and vascular development.
Ren H, Panchatcharam M, Mueller P, Escalante-Alcalde D, Morris AJ, et al.
Biochimica et biophysica acta. 2013; 1831(1):126-32. NIHMSID: NIHMS479227
Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.
Helsley RN, Sui Y, Ai N, Park SH, Welsh WJ, et al.
Molecular pharmacology. 2013; 83(6):1190-9.
Resveratrol protects against polychlorinated biphenyl-mediated impairment of glucose homeostasis in adipocytes.
Baker NA, English V, Sunkara M, Morris AJ, Pearson KJ, et al.
The Journal of nutritional biochemistry. 2013; 24(12):2168-74. NIHMSID: NIHMS527453
Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.
Su K, Sabeva NS, Wang Y, Liu X, Lester JD, et al.
Arteriosclerosis, thrombosis, and vascular biology. 2014; 34(1):26-33. NIHMSID: NIHMS596080
Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis.
Smyth SS, Mueller P, Yang F, Brandon JA, Morris AJ.
Arteriosclerosis, thrombosis, and vascular biology. 2014; 34(3):479-86. NIHMSID: NIHMS543582
Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability.
Panchatcharam M, Salous AK, Brandon J, Miriyala S, Wheeler J, et al.
Arteriosclerosis, thrombosis, and vascular biology. 2014; 34(4):837-45. NIHMSID: NIHMS561207
Bisphenol A increases atherosclerosis in pregnane X receptor-humanized ApoE deficient mice.
Sui Y, Park SH, Helsley RN, Sunkara M, Gonzalez FJ, et al.
Journal of the American Heart Association. 2014; 3(2):e000492.
IKKβ links vascular inflammation to obesity and atherosclerosis.
Sui Y, Park SH, Xu J, Monette S, Helsley RN, et al.
The Journal of experimental medicine. 2014; 211(5):869-86.
Thrombospondin1 deficiency attenuates obesity-associated microvascular complications in ApoE-/- mice.
Maimaitiyiming H, Clemons K, Zhou Q, Norman H, Wang S.
PloS one. 2015; 10(3):e0121403.